Merck's women's health spinoff goes public in NYSE debut; A Houston antibody player scores fresh funds to chase tumors
Looking to free up a cash windfall and looking to streamline the business, Merck has long planned to slice away its women’s health business into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
